These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9561077)
21. Characterization and mechanism of side-effects of Imagent BP (highly concentrated fluorocarbon emulsion) in swine. Flaim SF; Hazard DR; Hogan J; Peters RM Invest Radiol; 1991 Nov; 26 Suppl 1():S122-4; discussion S125-8. PubMed ID: 1808107 [No Abstract] [Full Text] [Related]
22. Indirect lymphography with perflubron emulsion. Preclinical and clinical results. Hanna G; Hopkins R; Flaim K; Leese P; Schmid-Schönbein G; Wolf GL Invest Radiol; 1994 Jun; 29 Suppl 2():S33-5. PubMed ID: 7928265 [No Abstract] [Full Text] [Related]
23. Perflenapent emulsion (EchoGen): a new long-acting phase-shift agent for contrast echocardiography. Grayburn P Clin Cardiol; 1997 Oct; 20(10 Suppl 1):I12-8. PubMed ID: 9383597 [TBL] [Abstract][Full Text] [Related]
24. Quantitative evaluation of imagent as an abdominal ultrasound contrast medium in dogs. Bahr A; Wrigley R; Salman M Vet Radiol Ultrasound; 2000; 41(1):50-5. PubMed ID: 10695881 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging. Hancock J; Dittrich H; Jewitt DE; Monaghan MJ Heart; 1999 Jun; 81(6):636-41. PubMed ID: 10336924 [TBL] [Abstract][Full Text] [Related]
26. Assessment of brain perfusion with echo contrast specific imaging modes and Optison. Hölscher T; Postert T; Meves S; Thies T; Ermert H; Bogdahn U; Wilkening W Acad Radiol; 2002 Aug; 9 Suppl 2():S386-8. PubMed ID: 12188285 [No Abstract] [Full Text] [Related]
27. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Noveck RJ; Shannon EJ; Leese PT; Shorr JS; Flaim KE; Keipert PE; Woods CM Anesth Analg; 2000 Oct; 91(4):812-22. PubMed ID: 11004031 [TBL] [Abstract][Full Text] [Related]
28. Assessment of Takayasu arteritis activity by carotid contrast-enhanced ultrasound. Magnoni M; Dagna L; Coli S; Cianflone D; Sabbadini MG; Maseri A Circ Cardiovasc Imaging; 2011 Mar; 4(2):e1-2. PubMed ID: 21406658 [No Abstract] [Full Text] [Related]
29. Perfluoroctyl bromide as a blood pool contrast agent for computed tomographic angiography. Fruman SA; Harned RK; Marcus D; Kaufman S; Swenson RB; Bernardino ME Acad Radiol; 1994 Oct; 1(2):151-3. PubMed ID: 9419479 [TBL] [Abstract][Full Text] [Related]
30. [The electroencephalographic effects of GABA when using perfluorocarbon emulsions in rats]. Vorob'ev VV; Gorelkova TF; Kukushkin NI; Kosarskiĭ LS Eksp Klin Farmakol; 1994; 57(4):11-3. PubMed ID: 7950771 [TBL] [Abstract][Full Text] [Related]
31. Effect of emulsion concentration on biodistribution of perflubron in tumor-bearing mice. Long DM; Witt BL; Escobar JA; Long RA Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):907-10. PubMed ID: 1391531 [TBL] [Abstract][Full Text] [Related]
32. Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography. Mendiolaza J; Baltasar JF; Anis A; Harrison J; Chen F; Klapholz M; Saric M J Clin Ultrasound; 2007 Oct; 35(8):462-4. PubMed ID: 17373683 [TBL] [Abstract][Full Text] [Related]
34. The potential clinical impact of perflubron emulsion on general sonography. Mattrey RF Invest Radiol; 1991 Nov; 26 Suppl 1():S186-7; discussion S198-200. PubMed ID: 1808123 [No Abstract] [Full Text] [Related]
35. [Computed tomographic studies on density kinetics after the bolus injection and infusion of perfluorooctylbromide (PFOB). Animal experimental studies]. Adam G; Günther RW; Prescher A; Goertz H; Schiffer C; Bruchmüller K; Limmer J Rofo; 1992 May; 156(5):487-91. PubMed ID: 1596555 [TBL] [Abstract][Full Text] [Related]
36. [Color-coded duplex sonography and ultrasound contrast media--detection of renal perfusion defects in experimental animals]. Fobbe F; Siegert J; Fritzsch T; Koch HC; Wolf KJ Rofo; 1991 Mar; 154(3):242-5. PubMed ID: 1849290 [TBL] [Abstract][Full Text] [Related]
37. [Intravenous perfluorocarbons. Artificial oxygen carriers and their medical applications]. Frietsch T; Lenz C; Waschke KF Dtsch Med Wochenschr; 2000 Apr; 125(15):465-72. PubMed ID: 10800445 [No Abstract] [Full Text] [Related]
38. Grey scale enhancement of rabbit liver and kidney by intravenous injection of a new lipid-coated ultrasound contrast agent. Liu P; Gao YH; Tan KB; Liu Z; Zuo S World J Gastroenterol; 2004 Aug; 10(16):2369-72. PubMed ID: 15285021 [TBL] [Abstract][Full Text] [Related]
39. Parenchymal enhancement and tumor visualization using a new sonographic contrast agent. Forsberg F; Liu JB; Merton DA; Rawool NM; Goldberg BB J Ultrasound Med; 1995 Dec; 14(12):949-57. PubMed ID: 8583531 [TBL] [Abstract][Full Text] [Related]
40. Value of the real-time myocardial contrast echocardiography for risk stratification and for the detection of significant coronary stenosis in patients with end-stage renal disease. Sobkowicz B; Tomaszuk-Kazberuk A; Malyszko J; Kalinowski M; Hryszko T; Kralisz P; Dobrzycki S; Malyszko J; Mysliwiec M; Musial WJ Nephrol Dial Transplant; 2007 Feb; 22(2):668-9. PubMed ID: 17050631 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]